Cargando…

Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis

The nucleotide analogue azacitidine (AZA) is currently the best treatment option for patients with high-risk myelodysplastic syndromes (MDS). However, only half of treated patients respond and of these almost all eventually relapse. New treatment options are urgently needed to improve the clinical m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diesch, Jeannine, Le Pannérer, Marguerite-Marie, Winkler, René, Casquero, Raquel, Muhar, Matthias, van der Garde, Mark, Maher, Michael, Herráez, Carolina Martínez, Bech-Serra, Joan J., Fellner, Michaela, Rathert, Philipp, Brooks, Nigel, Zamora, Lurdes, Gentilella, Antonio, de la Torre, Carolina, Zuber, Johannes, Götze, Katharina S., Buschbeck, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523560/ https://www.ncbi.nlm.nih.gov/pubmed/34663789 http://dx.doi.org/10.1038/s41467-021-26258-z

Ejemplares similares

Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients
por: Le Pannérer, Marguerite-Marie, et al.
Publicado: (2022)

Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy
por: Maher, Michael, et al.
Publicado: (2021)

Epigenetic-Transcriptional Regulation of Fatty Acid Metabolism and Its Alterations in Leukaemia
por: Maher, Michael, et al.
Publicado: (2018)

Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18
por: Maher, Michael, et al.
Publicado: (2021)

Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes
por: Palau, Anna, et al.
Publicado: (2017)

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
por: Diesch, Jeannine, et al.
Publicado: (2016)

Histone Modifications and Their Targeting in Lymphoid Malignancies
por: Fernández-Serrano, Miranda, et al.
Publicado: (2021)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia
por: Min, Chengyin, et al.
Publicado: (2017)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
por: Jilg, Stefanie, et al.
Publicado: (2019)

Structure of CbpA J-Domain Bound to the Regulatory Protein CbpM Explains Its Specificity and Suggests Evolutionary Link between CbpM and Transcriptional Regulators
por: Sarraf, Naghmeh S., et al.
Publicado: (2014)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
por: Bhatt, Anjali, et al.
Publicado: (2022)

Molecular dynamics simulations data of six compounds F3J-BRD4/CBP, EX1-BRD4/CBP, and E2T-BRD4/CBP
por: Wu, Shiliang, et al.
Publicado: (2021)

Improving extracellular production of Serratia marcescens lytic polysaccharide monooxygenase CBP21 and Aeromonas veronii B565 chitinase Chi92 in Escherichia coli and their synergism
por: Yang, Yalin, et al.
Publicado: (2017)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Azacitidine: No therapeutic response: case report
Publicado: (2020)

Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents
por: Chen, Qingjuan, et al.
Publicado: (2022)

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
por: Cabezón, M., et al.
Publicado: (2021)

Cbp3–Cbp6 interacts with the yeast mitochondrial ribosomal tunnel exit and promotes cytochrome b synthesis and assembly
por: Gruschke, Steffi, et al.
Publicado: (2011)

Cbp3–Cbp6 interacts with the yeast mitochondrial ribosomal tunnel exit and promotes cytochrome b synthesis and assembly
por: Gruschke, Steffi, et al.
Publicado: (2011)

The Cbp3–Cbp6 complex coordinates cytochrome b synthesis with bc(1) complex assembly in yeast mitochondria
por: Gruschke, Steffi, et al.
Publicado: (2012)

The 40S-LARP1 complex reprograms the cellular translatome upon mTOR inhibition to preserve the protein synthetic capacity
por: Fuentes, Pedro, et al.
Publicado: (2021)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human disease
por: Diesch, Jeannine, et al.
Publicado: (2014)

Genome wide mapping of UBF binding-sites in mouse and human cell lines
por: Diesch, Jeannine, et al.
Publicado: (2015)

Protein Lysine Acetylation by p300/CBP
por: Dancy, Beverley M., et al.
Publicado: (2015)

Azacitidine in outpatient treatment – single center experience
por: Rybka, Justyna, et al.
Publicado: (2016)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
por: Stopka, Tomáš, et al.
Publicado: (2022)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Curcumin, COX-2, and Protein p300/CBP
por: Jung, Ki Tae, et al.
Publicado: (2014)

Dimeric structure of p300/CBP associated factor
por: Shi, Shasha, et al.
Publicado: (2014)

CBP binding outside of promoters and enhancers in Drosophila melanogaster
por: Philip, Philge, et al.
Publicado: (2015)

Alcohol-Induced Neuroadaptation Is Orchestrated by the Histone Acetyltransferase CBP
por: Ghezzi, Alfredo, et al.
Publicado: (2017)

Correction to Protein Lysine Acetylation by p300/CBP
por: Dancy, Beverley M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qpi7b77vkkaha8bb7a6fqubsi5